Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL By admin / 12/07/2020
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study By admin / 11/04/2020
